# AGIO catalysts: AGIOS PHARMACEUTICALS, INC. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/agio/catalysts

> AGIOS PHARMACEUTICALS, INC. (AGIO) has 10 upcoming catalysts. The next is the AQVESME™ (mitapivat) PDUFA date, February 1, 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, half-year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for AGIO?

AGIOS PHARMACEUTICALS, INC. (AGIO) has 10 upcoming catalysts. The next is the AQVESME™ (mitapivat) PDUFA date, February 1, 2027. Press release filed with the SEC (EX-99): "•New PDUFA goal date for mitapivat sickle cell disease sNDA set for February 1, 2027; company is launch-ready and in labeling discussions with FDA" [Calendar and source filings](https://sec-api.dev/companies/agio/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001439222-26-000129, https://www.sec.gov/Archives/edgar/data/1439222/000143922226000129/agio-110526xfyxex991earnin.htm (retrieved 2026-11-12). Last confirmed 2026-11-05. Cite: https://sec-api.dev/companies/agio/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | AGIOS PHARMACEUTICALS, INC. |
| Ticker | AGIO (Nasdaq) |
| SEC CIK | 1439222 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/agio |

## Cash runway

Cash $907.0M as of 2026-09-30; quarterly burn $59.2M; about 45.9 months of runway at that rate (XBRL company facts, accession 0001439222-26-000131).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Feb 2022 | [PYRUKYND® (pyrukynd) FDA approval](https://sec-api.dev/pdufa/pyrukynd) | AGIO |  | completed, approved | "Total Revenue - 2023 vs. 2022 - The increase in total revenue of $12.6 million in 2023 compared to 2022 was due to increased product revenue associated with PYRUKYND®, which was approved by the FDA in February 2022, partially offset by revenue recognized in 2022 associated with the licensing of intellectual property for our Friedreich's Ataxia preclinical program." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1439222/000143922225000009/agio-20241231.htm)) |
| Dec 2024 | [PYRUKYND® (pyrukynd) NDA/BLA submission](https://sec-api.dev/pdufa/pyrukynd) | AGIO |  | completed | "In December 2024, we announced that we submitted a supplemental new drug application, or sNDA, to the FDA for PYRUKYND® for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1439222/000143922225000116/agio-20250930.htm)) |
| Dec 2024 | [PYRUKYND® (pyrukynd) NDA/BLA acceptance](https://sec-api.dev/pdufa/pyrukynd) | AGIO |  | completed | "In December 2024, we announced that we submitted a supplemental new drug application, or sNDA, to the FDA for PYRUKYND® for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia, which was accepted with standard review by the FDA and granted a Prescription Drug User Fee Act, or PDUFA, goal date of September 7, 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1439222/000143922225000089/agio-20250630.htm)) |
| February 13, 2025 | [AQVESME™ (mitapivat) topline data readout](https://sec-api.dev/pdufa/mitapivat) | AGIO |  | completed, positive | "◦Reported in a separate press release today, positive topline results from the ACTIVATE-Kids Phase 3 study of mitapivat in children aged 1 to <18 years with PK deficiency who are not regularly transfused." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1439222/000143922225000007/agio-021325xfyxex991earnin.htm)) |
| February 13, 2025 | [AGIOS PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/agio/catalysts) | AGIO |  | completed | "Agios Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1439222/000143922225000007/agio-021325xfyxex991earnin.htm)) |
| May 1, 2025 | [AGIOS PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/agio/catalysts) | AGIO |  | completed | "Agios Reports First Quarter 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1439222/000143922225000034/agio-050125xfyxex991earnin.htm)) |
| Jun 2025 | [AG-236 trial start](https://sec-api.dev/pdufa/ag-236) | AGIO |  | completed | "We filed an IND with the FDA for AG-236 for the treatment of PV, which cleared in June 2025, and we initiated a phase 1 clinical trial evaluating AG-236 in healthy volunteers in July 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1439222/000143922226000025/agio-20251231.htm)) |
| July 31, 2025 | [AGIOS PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/agio/catalysts) | AGIO |  | completed | "Agios Reports Second Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1439222/000143922225000087/agio-073125xfyxex991earnin.htm)) |
| late 2025 | [AQVESME™ (mitapivat) topline data readout](https://sec-api.dev/pdufa/mitapivat) | AGIO |  | scheduled | "- Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease On Track, with Topline Results Expected in Late 2025; Potential U.S. Commercial Launch in 2026 -" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1439222/000143922225000034/agio-050125xfyxex991earnin.htm)) |
| late 2025 | [AGIOS PHARMACEUTICALS, INC. topline data readout](https://sec-api.dev/companies/agio/catalysts) | AGIO |  | scheduled | "We have completed enrollment and expect to announce topline data for this trial in late 2025, with a potential U.S. commercial launch in 2026, if approved." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1439222/000143922225000116/agio-20250930.htm)) |
| late 2025 | [AGIOS PHARMACEUTICALS, INC. topline data readout](https://sec-api.dev/companies/agio/catalysts) | AGIO |  | scheduled | ""Looking ahead, our focus is also on delivering the topline results from the Phase 3 RISE UP study in sickle cell disease, which remains on track for year-end, and continuing to advance our early and mid-stage clinical programs." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1439222/000143922225000034/agio-050125xfyxex991earnin.htm)) |
| late 2025 | [PYRUKYND® (pyrukynd) topline data readout](https://sec-api.dev/pdufa/pyrukynd) | AGIO |  | scheduled | "PYRUKYND® in Sickle Cell Disease with Expected Readout in Late 2025 Abbreviations: BID = twice daily; Hb = hemoglobin; SCPC = sickle cell pain crises; HU = hydroxyurea (1) Phase 2 and phase 3 components are part of a single study/protocol; (2)" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1439222/000119312525004943/d131665dex992.htm)) |
| September 7, 2025 | [PYRUKYND® (pyrukynd) PDUFA date](https://sec-api.dev/pdufa/pyrukynd) | AGIO | Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia | delayed | "•PYRUKYND sNDA for thalassemia under active review, with FDA PDUFA goal date of September 7, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1439222/000143922225000087/agio-073125xfyxex991earnin.htm)) |
| September 7, 2025 | [PYRUKYND® (pyrukynd) NDA/BLA acceptance](https://sec-api.dev/pdufa/pyrukynd) | AGIO |  | completed | "The FDA accepted the sNDA and granted a PDUFA goal date of September 7, 2025, which the FDA subsequently extended to December 7, 2025 following our submission of a proposed REMS to mitigate the risk of hepatocellular injury that was described in the original PYRUKYND® sNDA." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1439222/000143922225000116/agio-20250930.htm)) |
| October 30, 2025 | [AGIOS PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/agio/catalysts) | AGIO |  | completed | "Agios Reports Third Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1439222/000143922225000114/agio-103125xfyxex991earnin.htm)) |
| October 30, 2025 | [AQVESME™ (mitapivat) primary completion](https://sec-api.dev/pdufa/mitapivat) | AGIO | Sickle Cell Disease | completed | "NCT05031780 (A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2025-10-30 (ACTUAL); Lead Sponsor Agios Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05031780)) |
| Dec 2025 | [AQVESME™ (mitapivat) FDA approval](https://sec-api.dev/pdufa/mitapivat) | AGIO | anemia in adults with alpha- or beta-thalassemia | completed, approved | "◦In December 2025, the U.S. Food and Drug Administration (FDA) approved AQVESME as the only medicine for the treatment of anemia in adults with alpha- or beta-thalassemia, regardless of transfusion burden." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1439222/000143922226000023/agio-21226xfyxex991earning.htm)) |
| December 7, 2025 | [PYRUKYND® (pyrukynd) PDUFA date](https://sec-api.dev/pdufa/pyrukynd) | AGIO |  | scheduled | "•PDUFA goal date for PYRUKYND U.S. sNDA in thalassemia set for December 7, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1439222/000143922225000114/agio-103125xfyxex991earnin.htm)) |
| 1H 2026 | [Tebapivat topline data readout](https://sec-api.dev/pdufa/tebapivat) | AGIO |  | scheduled | "Safety Tebapivat Phase 2b trial for LR-MDS1 N=60 10mg QD 15mg QD 20mg QD 24 weeks Open-label period2 Extension Period (tebapivat 10mg, 15mg, 20mg) 156 weeks Phase 2b topline data expected H1 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1439222/000143922226000018/a0112026_jpm2026xagiospr.htm)) |
| 1H 2026 | [AQVESME™ (mitapivat) topline data readout](https://sec-api.dev/pdufa/mitapivat) | AGIO |  | scheduled | "Agios expects to report topline results from its Phase 2b trial in the first half of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1439222/000143922226000071/agio-42926xfyxex991earning.htm)) |
| 1H 2026 | [AG-236 topline data readout](https://sec-api.dev/pdufa/ag-236) | AGIO |  | scheduled | "-Agios expects to report topline results from a Phase 1 healthy volunteer trial of AG-236, a small interfering RNA (siRNA) targeting TMPRSS6 as a potential treatment for PV, in the first half of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1439222/000143922226000018/agio-011226xprxex991.htm)) |
| 1H 2026 | [AGIOS PHARMACEUTICALS, INC. topline data readout](https://sec-api.dev/companies/agio/catalysts) | AGIO |  | scheduled | "Agios expects to report topline results from this trial in the first half of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1439222/000143922226000018/agio-011226xprxex991.htm)) |
| 1H 2026 | [Stabilizer trial start](https://sec-api.dev/pdufa/stabilizer) | AGIO |  | scheduled | "-With dosing completed in the Phase 1 single- and multiple-ascending-dose trial of AG-181, a phenylalanine hydroxylase (PAH) stabilizer, in healthy volunteers, Agios expects to initiate a Phase 1b proof-of-mechanism trial of AG-181 in patients with PKU in the first half of 2026 and to confirm proof of mechanism in the second half of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1439222/000143922226000018/agio-011226xprxex991.htm)) |
| 1H 2026 | [AGIOS PHARMACEUTICALS, INC. topline data readout](https://sec-api.dev/companies/agio/catalysts) | AGIO |  | scheduled | "We completed enrollment in the phase 2b portion of the trial in September 2025 and expect to announce topline data for this trial in the first half of 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1439222/000143922226000073/agio-20260331.htm)) |
| February 12, 2026 | [AGIOS PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/agio/catalysts) | AGIO |  | completed | "Agios Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1439222/000143922226000023/agio-21226xfyxex991earning.htm)) |
| March 17, 2026 | [Tebapivat primary completion](https://sec-api.dev/pdufa/tebapivat) | AGIO | Myelodysplastic Syndromes | completed | "NCT05490446 (A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-03-17 (ACTUAL); Lead Sponsor Agios Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05490446)) |
| Q2 2026 | [AQVESME™ (mitapivat) NDA/BLA submission](https://sec-api.dev/pdufa/mitapivat) | AGIO |  | scheduled | "•Company plans to submit mitapivat sNDA for sickle cell disease in the second quarter of 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1439222/000143922226000071/agio-42926xfyxex991earning.htm)) |
| April 29, 2026 | [AGIOS PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/agio/catalysts) | AGIO |  | completed | "Agios Reports First Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1439222/000143922226000071/agio-42926xfyxex991earning.htm)) |
| May 12, 2026 | [Tebapivat primary completion](https://sec-api.dev/pdufa/tebapivat) | AGIO | Sickle Cell Disease | completed | "NCT06924970 (A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-05-12 (ACTUAL); Lead Sponsor Agios Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06924970)) |
| 2H 2026 | [Tebapivat topline data readout](https://sec-api.dev/pdufa/tebapivat) | AGIO |  | scheduled | "•Phase 2 tebapivat trial in sickle cell disease fully enrolled; topline results expected in second half of 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1439222/000143922226000023/agio-21226xfyxex991earning.htm)) |
| 2H 2026 | [AG-236 trial start](https://sec-api.dev/pdufa/ag-236) | AGIO |  | scheduled | "We expect to initiate the phase 2 portion of a phase 2/3 trial of AG-236 in patients with PV in the second half of 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1439222/000143922226000131/agio-20260930.htm)) |
| 2H 2026 | [AGIOS PHARMACEUTICALS, INC. topline data readout](https://sec-api.dev/companies/agio/catalysts) | AGIO |  | scheduled | "Agios expects to report topline results from this trial in the second half of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1439222/000143922226000018/agio-011226xprxex991.htm)) |
| 2H 2026 | [AQVESME™ (mitapivat) topline data readout](https://sec-api.dev/pdufa/mitapivat) | AGIO |  | scheduled | "Agios expects to report topline results from its Phase 2 trial in the second half of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1439222/000143922226000071/agio-42926xfyxex991earning.htm)) |
| July 30, 2026 | [AGIOS PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/agio/catalysts) | AGIO |  | completed | "Agios Reports Second Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1439222/000143922226000115/agio-73026xfyxex991earning.htm)) |
| November 1, 2026 | [AQVESME™ (mitapivat) PDUFA date](https://sec-api.dev/pdufa/mitapivat) | AGIO |  | scheduled | "•sNDA for mitapivat granted FDA Priority Review in sickle cell disease with PDUFA goal date of November 1, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1439222/000143922226000115/agio-73026xfyxex991earning.htm)) |
| November 5, 2026 | [AGIOS PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/agio/catalysts) | AGIO |  | completed | "Agios Reports Third Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1439222/000143922226000129/agio-110526xfyxex991earnin.htm)) |
| February 1, 2027 | [AQVESME™ (mitapivat) PDUFA date](https://sec-api.dev/pdufa/mitapivat) | AGIO | sickle cell disease | scheduled | "•New PDUFA goal date for mitapivat sickle cell disease sNDA set for February 1, 2027; company is launch-ready and in labeling discussions with FDA" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1439222/000143922226000129/agio-110526xfyxex991earnin.htm)) |
| 1H 2028 | [Cevidoplenib trial start](https://sec-api.dev/pdufa/cevidoplenib) | AGIO |  | scheduled | "We expect to initiate a phase 3 clinical trial of cevidoplenib in patients with ITP in the first half of 2028, following completion of additional chemistry, manufacturing and controls development work." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1439222/000143922226000131/agio-20260930.htm)) |
| March 2029 | [AQVESME™ (mitapivat) primary completion](https://sec-api.dev/pdufa/mitapivat) | AGIO | Non-Transfusion-dependent Alpha-Thalassemia; Non-Transfusion-dependent Beta-Thalassemia | scheduled | "NCT07517133 (A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With α- or β-Non-Transfusion-Dependent Thalassemia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-03 (ESTIMATED); Lead Sponsor Agios Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07517133)) |
| Mar to Jun 2029 | [AQVESME™ (mitapivat) topline data readout](https://sec-api.dev/pdufa/mitapivat) | AGIO | Non-Transfusion-dependent Alpha-Thalassemia; Non-Transfusion-dependent Beta-Thalassemia | scheduled | "NCT07517133 (A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With α- or β-Non-Transfusion-Dependent Thalassemia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-03 (ESTIMATED); Lead Sponsor Agios Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07517133)) |
| June 2029 | [AQVESME™ (mitapivat) primary completion](https://sec-api.dev/pdufa/mitapivat) | AGIO | Transfusion-dependent Alpha-Thalassemia; Transfusion-dependent Beta-Thalassemia | scheduled | "NCT07506863 (A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-06 (ESTIMATED); Lead Sponsor Agios Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07506863)) |
| Jun to Sep 2029 | [AQVESME™ (mitapivat) topline data readout](https://sec-api.dev/pdufa/mitapivat) | AGIO | Transfusion-dependent Alpha-Thalassemia; Transfusion-dependent Beta-Thalassemia | scheduled | "NCT07506863 (A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-06 (ESTIMATED); Lead Sponsor Agios Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07506863)) |
| August 2029 | [AQVESME™ (mitapivat) primary completion](https://sec-api.dev/pdufa/mitapivat) | AGIO | Sickle Cell Disease | scheduled | "NCT07656415 (A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-08 (ESTIMATED); Lead Sponsor Agios Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07656415)) |
| Aug to Nov 2029 | [AQVESME™ (mitapivat) topline data readout](https://sec-api.dev/pdufa/mitapivat) | AGIO | Sickle Cell Disease | scheduled | "NCT07656415 (A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-08 (ESTIMATED); Lead Sponsor Agios Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07656415)) |
| August 2030 | [AG-236 primary completion](https://sec-api.dev/pdufa/ag-236) | AGIO | Polycythemia Vera | scheduled | "NCT07859423 (A Study to Investigate AG-236 in Subjects ≥18 Years of Age With Polycythemia Vera): Overall Status NOT_YET_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2030-08 (ESTIMATED); Lead Sponsor Agios Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07859423)) |
| Aug to Nov 2030 | [AG-236 topline data readout](https://sec-api.dev/pdufa/ag-236) | AGIO | Polycythemia Vera | scheduled | "NCT07859423 (A Study to Investigate AG-236 in Subjects ≥18 Years of Age With Polycythemia Vera): Overall Status NOT_YET_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2030-08 (ESTIMATED); Lead Sponsor Agios Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07859423)) |

## Drugs

- [AG-236](https://sec-api.dev/pdufa/ag-236): Polycythemia Vera
- [Cevidoplenib](https://sec-api.dev/pdufa/cevidoplenib): 
- [AQVESME™ (mitapivat)](https://sec-api.dev/pdufa/mitapivat): sickle cell disease, anemia in adults with alpha- or beta-thalassemia, regardless of transfusion burden, anemia in adults with alpha- or beta-thalassemia, non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, Non-Transfusion-dependent Alpha-Thalassemia, Transfusion-dependent Alpha-Thalassemia
- [PYRUKYND® (pyrukynd)](https://sec-api.dev/pdufa/pyrukynd): 
- [Stabilizer](https://sec-api.dev/pdufa/stabilizer): 
- [Tebapivat](https://sec-api.dev/pdufa/tebapivat): Sickle Cell Disease, Myelodysplastic Syndromes

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/agio/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "AGIO catalysts: AGIOS PHARMACEUTICALS, INC. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/agio/catalysts

```bibtex
@misc{secapidev_companies_agio_catalysts_20261116,
  title        = {AGIO catalysts: AGIOS PHARMACEUTICALS, INC. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/agio/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_agio_catalysts_20261116","title":"AGIO catalysts: AGIOS PHARMACEUTICALS, INC. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/agio/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
